APA (7th ed.) Citation

B, G., JN, S., MA, F., DL, B., A, S., H, B., . . . L, E. (2024). MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. BioRxiv : the preprint server for biology. https://doi.org/10.1101/2024.01.31.578216

Chicago Style (17th ed.) Citation

B, German, et al. "MYBL2 Drives Prostate Cancer Plasticity and Identifies CDK2 as a Therapeutic Vulnerability in RB1-loss and Neuroendocrine Prostate Cancer." BioRxiv : The Preprint Server for Biology 2024. https://doi.org/10.1101/2024.01.31.578216.

MLA (9th ed.) Citation

B, German, et al. "MYBL2 Drives Prostate Cancer Plasticity and Identifies CDK2 as a Therapeutic Vulnerability in RB1-loss and Neuroendocrine Prostate Cancer." BioRxiv : The Preprint Server for Biology, 2024, https://doi.org/10.1101/2024.01.31.578216.